ClinicalTrials.gg
CompletedNCT00973323Updated Dec 30, 2014

BAY59-7939 Japanese in Atrial Fibrillation (2nd)

A Phase 2 interventional study of Xarelto (Rivaroxaban, BAY59-7939) and Xarelto (Rivaroxaban, BAY59-7939) in Atrial Fibrillation, sponsored by Bayer. Completed at 10 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2014-12-30.

Sponsored by Bayer · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 45 studies testing rivaroxaban in Atrial Fibrillation — 8 open to participants now, 9 under way, none of them phase 3. Rivaroxaban · Atrial Fibrillation.

Enrollment
27th of 45
100 · median 150
Started
2005
the only one that year
Phase 2
3 of 45
none open now
Registered
4th of 45
by date
Lead sponsor
8 of 45
Bayer

Among the 45 studies testing rivaroxaban in Atrial Fibrillation, this one is the 27th largest by enrollment, is the only one that started in 2005, is one of 3 in phase 2, and was the 4th registered.

Atrial Fibrillation

4,011 studies on the registry are indexed under Atrial Fibrillation; 961 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

8 of the 45 studies testing rivaroxaban in Atrial Fibrillation are open now, in 4 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About rivaroxaban

Rivaroxaban: first FDA approval 2011 (XARELTO), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 611 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies testing rivaroxaban in Atrial Fibrillation, or all of them as a file.
02

Study summary

This study was a randomized, parallel group, open label trial using warfarin as comparator. Pharmacokinetics (PK) and pharmacodynamics (PD) were investigated only in BAY59-7939 groups (originally described in Japanese).

03

Conditions studied

  • Atrial Fibrillation

Browse trials for

Keywords

  • BAY59-7939
  • Rivaroxaban
  • Non-valvular atrial fibrillation
  • Japanese Patients
  • Phase II
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Japanese subjects with non-valvular AF who met all of the following criteria:

    • Persistent or paroxysmal non-valvular AF with >/=2 episodes before enrollment, at least 1 of which had been verified by recording within 4 weeks before randomization
    • Male subjects aged 20 years or older and female subjects
    • Subjects with at least one risk factor for thromboembolism or aged 60 years or older (Risk factor for thromboembolism: hypertension, diabetes mellitus, coronary artery disease, congestive heart failure).

Exclusion criteria

Exclusion Criteria:

  • History or presence of stroke or .
  • History of intracerebral hemorrhage.
  • History or presence of bleeding at randomization; intraocular or gastrointestinal bleeding within the last 6 months prior to randomization.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Arm 1

    Drug: Xarelto (Rivaroxaban, BAY59-7939)

  • Experimental
    Arm 2

    Drug: Xarelto (Rivaroxaban, BAY59-7939)

  • Experimental
    Arm 3

    Drug: Xarelto (Rivaroxaban, BAY59-7939)

  • Active comparator
    Arm 4

    Drug: Warfarin

Interventions

06

What researchers measure

Primary outcomes

  1. (Safety) Incidence of bleeding

    Time frame: Throughout treatment and followup period

  2. (PK/PD) BAY 59-7939 concentrations / Factor Xa activity, PT, PT-INR, PTT and HEPTEST

    Time frame: Day 14 and Day 28

07

Study locations

10 sites
  • Kurume, Fukuoka 830-8577, Japan
  • Maebaru, Fukuoka 819-1104, Japan
  • Kitahiroshima, Hokkaido 061-1134, Japan
  • Kushiro, Hokkaido 085-0831, Japan
  • Sapporo, Hokkaido 064-0807, Japan
  • Nomi, Ishikawa 923-1100, Japan
  • Yokohama, Kanagawa 227-0046, Japan
  • Tokorozawa, Saitama 359-1141, Japan
  • Fukui, 910-0005, Japan
  • Oita, 870-0192, Japan
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2005 and a completion of Mar 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2009
First posted
Sep 9, 2009
Start
Sep 2005
CompletionActual
Mar 2006
Last update
Dec 30, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 30, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00973323
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Sep 9, 2009
Start date
Sep 2005
Completion
Mar 2006
Last update
Dec 30, 2014

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rivaroxaban

Start the discussion